Evidence map›Paper›PMID 39979757›Full record

ReviewAAPS PharmSciTech2025

Nanocrystals for Intravenous Drug Delivery: Composition Development, Preparation Methods and Applications in Oncology.

Wanjiao Chen, Jingyi Huang, Yankun Guo, Xinyv Wang, Zhizhe Lin, Ruting Wei, Jianming Chen, Xin Wu

Abstract readReview
PubMed Publisher
In one paragraph

Review in AAPS PharmSciTech, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Wanjiao ChenFujian University of Traditional Chinesemedicine, No. 1 Qiuyang Road, Fuzhou, 350122, China.
Jingyi HuangFujian University of Traditional Chinesemedicine, No. 1 Qiuyang Road, Fuzhou, 350122, China.
Yankun GuoShanghai General Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, 85 Wujin Road, Hongkou District, Shanghai, 200080, China.
Xinyv WangShanghai Wei Er Lab, Shanghai, 201707, China.
Zhizhe LinShanghai Wei Er Lab, Shanghai, 201707, China.
Ruting WeiFujian University of Traditional Chinesemedicine, No. 1 Qiuyang Road, Fuzhou, 350122, China.
Jianming ChenFujian University of Traditional Chinesemedicine, No. 1 Qiuyang Road, Fuzhou, 350122, China. chenjm0711@163.com.
Xin WuFujian University of Traditional Chinesemedicine, No. 1 Qiuyang Road, Fuzhou, 350122, China. wuxin007@126.com.ORCID http://orcid.org/0000-0003-2875-355X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Intravenous routes of drug delivery are widely used in clinical practice due to the advantages of fast onset of action and avoidance of first-pass effect. Still, it is difficult to develop poorly water-soluble drugs for intravenous administration. In recent years, the application of nanocrystal technology has become more and more widespread, mainly involving reducing the particle size to the nanoparticle size range and improving its physicochemical properties to enhance the bioavailability of drugs. Intravenous nanocrystals (INCs) can show unique advantages in the vasculature, with their high drug loading capacity, low toxicity, and overcoming low solubility, which makes them a new solution in tumor therapy. In addition, INCs are mainly suspended in aqueous/oil phase media, which makes them easy to inject. Therefore, INCs may serve as a novel strategy to address poor water solubility, low bioavailability, and associated toxicity. This review contains the compositional development of INCs, and preparation methods, and provides some insights into their application in oncology.

Indexed as

Antineoplastic AgentsDrug Delivery SystemsNanoparticlesNeoplasmsAdministration, IntravenousAnimalsBiological AvailabilityChemistry, PharmaceuticalHumansParticle SizeSolubilityAntineoplastic AgentsComposition developmentIntravenous nanocrystalsOncology applicationsPreparation process

Identifiers

PMID39979757

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.